Skip To Main Content
Istvan Toth on Muck Rack

Istvan Toth

As seen in: Medium, Nature, Wiley Online Library, MDPI, Royal Society of Chemistry, American Thinker, The Journal of Allergy & Clinical Immunology, Le Grand Continent, Lucianne.com, The Daily Sceptic and

Get in touch with Istvan

Contact Istvan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

The Masks Are Off: How Europe Betrayed the Trump Administration

|
By Istvan Toth, István Tóth
| American Thinker Verified
Europe has betrayed President Trump. For years, EU leaders and key national governments have undermined the White House's agenda quietly, working to remove pro-Washington figures from power. We recently witnessed this in Romania, where Cătălin Georgescu -- a clear frontrunner who favored closer ties with the U.S. -- was effectively sidelined in the presidential race. In Hungary, there was a concerted effort to defeat Viktor Orbán and his Fidesz party in April.
Open in Who Shared Issue with article?

Hungary: A Thorny Transition After The Election

|
By Istvan Toth, István Tóth
| American Thinker Verified
The Red Pill of Reality Hungarian Prime Minister Viktor Orbán and his Fidesz party were unexpectedly defeated in the April 12 parliamentary elections. Supporters of Péter Magyar’s Tisza party are celebrating their victory, having received nods of approval and handshakes from Brussels and many other European capitals. Eurocrats are rushing to declare the end of the “Orbán era.” However, Tisza did not win because its platform was more compelling. Hungarian society simply craved change.
Open in Who Shared Issue with article?

Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities

|
By Melaku Ashagrie Belete, Istvan Toth, István Tóth, Rachel E. Stephenson, Mariusz Skwarczynski
| Nature Verified
Abstract Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pathogen interactions, risk of autoimmunity and lack of clear correlates of protection. This review discusses recent advances in GAS vaccine research, highlights key challenges and outlines criteria and emerging opportunities for antigen selection.
Open in Who Shared Issue with article?
See all 24 articles